TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: OIIRR for lower central incisors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Neurological function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Daily living ability improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in extracellular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Attainment of moderation in drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FA value of the caudate nucleus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart/mediastinum MIBG uptake (H/M ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Duration of supplemental oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Horizontal Probing Depth (HPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Class I defects postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: interlimb volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sum of interlimb arm circumferences change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bioimpedence spectroscopy change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported lymphedema symptoms change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lymphedema exacerbation requiring treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Skeletal muscle citrate synthase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality rate in children with AP
Endpoint domain: Mortality/survival
Primary endpoint: spatiotemporal measures of gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brushing duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular death, myocardial infarction, or ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Postoperative CFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cure effect evaluated by VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients completely dry (ICIQ-UI SF questionnaire)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients dry or improved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower doses to organs at risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Equivalent uniform doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monitor units required
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Knowledge of cancer risk factors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: overall survival at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: failure-free survival at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differential metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of drinks per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alcohol-related problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of alcohol use disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alcohol cravings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASAS 20% response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptom load reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: transit time of contrast medium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: contrast enhancement on indirect portography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum titanium level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum vanadium level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum aluminum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality at hospital discharge
Endpoint domain: Mortality/survival
Primary endpoint: Neurodevelopmental outcomes at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: multiple pregnancy rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in PANSS total response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tolerance of IPL treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: efficacy of IPL treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in the state of the corneoconjunctival epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief of dry eye symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-months heart failure incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 3-months mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: 3-months re-infarction risk
Endpoint domain: Adverse events/effects
Primary endpoint: Time to onset of angina pectoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in anxiety (NPI/NH Anxiety item)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: WMT score improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: combined response at 24 weeks post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response rates at 1 year post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: cardiac survival
Endpoint domain: Mortality/survival
Primary endpoint: significant coronary artery disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: severe coronary artery disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in V˙O2peak (ΔV˙O2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: annualized exacerbation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: number of severe exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: All-cause death or hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Good response after 8 weeks of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of symptomatology by at least 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of angina episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: risk reductions in teen driving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost towards stoma care
Endpoint domain: Resource use
Primary endpoint: Dermatology Life Quality Index score of 1 or less
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvements in itch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental shuttle walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyspnoea
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: frequency of gastric contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: frequency of small intestinal contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: velocity of the magnetic pill in the small intestine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: cardiovascular disease risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of severe nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Score for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum tumor enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: carotid arterial enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower mortality
Endpoint domain: Mortality/survival
Primary endpoint: Adverse reactions to formula
Endpoint domain: Adverse events/effects
Primary endpoint: sensitivity rate of peritoneal endometriosis detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with unfavorable outcome
Endpoint domain: Mortality/survival
Primary endpoint: long-term cognitive outcomes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: socially engaged imitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative levels of CK‐MB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Primary patency at 2 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rebleeding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: cumulative rebleeding-free proportion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in Block design subtest scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Similarities subtest scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Back-specific functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to clinical decision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of incontinence symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of developing at least weekly incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative transport time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in pain, tenderness, and joint activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in PASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Catatonia severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to antipsychotic medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Berg Balance Scale mean score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison of ventricular rate control with rhythm control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of severe OM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: opioid use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total bleeding episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total bleeding episodes per year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reticular dermal volume increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elastin content increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hyaluronic acid increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: children's blood lead levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: large-LDL particle concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: large-HDL particle concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: plasma apoAI concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: thrombus formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of BOP (Bleeding on Probing)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in clinical AL (Attachment Level)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracranial hemorrhage volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg-extension 1RM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Quadriceps cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle fiber hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: plasma total homocysteine (tHcy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: postprandial total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fasting lipid indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Return to work during the first postpartum year
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: inflammatory and noninflammatory lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: acne severity assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: reduction in sebum secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Decreases in glycated hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tremor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perineal pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of heavy drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of ONJ
Endpoint domain: Adverse events/effects
Primary endpoint: Correct melanoma and benign lesion discrimination rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased desire to use cocaine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fine motor function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV-specific antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: B cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fibrillation Cycle Length (FCL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Fibrillation Cycle Length (DeltaFCL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: T cell numbers in lesional epidermis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T cell numbers in synovial tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Macrophage numbers in synovial sublining
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Survival at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: One year survival with favorable functional outcome
Endpoint domain: Mortality/survival
Primary endpoint: Weight change (Kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI change (kg/m2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of myocardial injury marker troponin I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity of smears and cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean growth time for positive cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypermetropia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structured Clinical Interview for Separation Anxiety Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life Enjoyment and Satisfaction Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in mite numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of erythematous patches
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Hair regrowth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: maximum plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: area under the plasma concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in average pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients reporting at least a 30% improvement in pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications (graft scarring, granuloma, proliferation)
Endpoint domain: Adverse events/effects
Primary endpoint: Ulcer healing outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to healing with intact skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to ST segment depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Progression of atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IPSS obstructive subscores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: In-gate percentage of MPO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Average fluorescent intensity of MPO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Nitrogen loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle GLN concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: symptom-limited exercise duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: onset of persistent ST-segment depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: weekly anginal episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Psoriasis Area Severity Index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of PHNC role on physical healthcare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SVV (Stroke Volume Variation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Timely discontinuation of postoperative antibacterials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of leucine appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endogenous glutamine due to protein breakdown
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: FT scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: SF-6D scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Esophageal patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Higher free testosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes